Skip to site menu Skip to page content

Daily Newsletter

29 October 2024

Daily Newsletter

29 October 2024

Exer AI and Mayo Clinic unite to treat hand and wrist disorders using AI

Exer’s AI-based software analyses hand and wrist motion using a camera to diagnose conditions and recommend treatments.

Jenna Philpott September 06 2024

Clinical AI company Exer AI and the Mayo Clinic are teaming up to diagnose and treat acute and chronic hand and wrist disorders using Exer’s AI-based technology. 

US-based Exer’s proprietary AI and computer vision platform can be used to assess and monitor motion disorders without sensors, wearables, or human error. It can also monitor the severity and progress of disorders to collect patient outcome data, and even diagnose disorders.

The collaboration focuses on protocols to perform in-clinic, remote and telehealth assessments for a range of hand and wrist conditions including carpel tunnel, rheumatoid arthritis, and distal radius fractures. 

Validated as a US Food and Drug Administration (FDA) Class II Medical Device, the software analyses hand and wrist motion using a camera, taking measures such as total active motion, Kapandji score, flexion/extension, and pronation/supination.

With the help of AI, it can diagnose conditions and recommend treatments. It can be used in the clinic, via telehealth, or at home.  

It is not the first partnership for the Mayo Clinic in the AI sector. In June 2024, the clinic partnered with UltraSight to advance cardiac care using AI in point-of-care ultrasound (PoCUS). As part of the collaboration, the two entities will develop algorithms for the analysis and interpretation of cardiac ultrasound images, as well as develop a comprehensive solution and decision support system. 

The AI revolution is taking place across the medical device industry. According to a report on GlobalData’s Medical Intelligence Center, AI in the medical market was worth $336m in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 29.1% to $1.2bn by 2027.

Founded in 2019, Exer secured $6.5m in a 2022 seed funding round that saw participation from Backstage Capital, Life Extension Ventures, and others.

Exer’s CEO Zaw Thet said: “Our approach is to innovate on top of our proprietary AI models to produce vital clinical software modules that don't rely on expensive hardware or invasive sensors. We designed the Exer platform to address motion disorders that span specialities like hand and wrist, neurology, pain/spine, PM&R, orthopaedics, and geriatrics to offer large health systems a complete solution they can trust to improve care at scale.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close